Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells

Cancer Immunology, Immunotherapy

Volumn 57, Issue 3, 2008, Pages 347-358

  Ryan, Elizabeth P ^a   Bushnell, Timothy P ^a   Friedman, Alan E ^a   Rahman, Irfan ^a   Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

B cells; Cox 2; Glutathione; Lymphoma; Oxidative stress

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; CAY 10404; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FURETHIDINE; GLUTATHIONE; MESSENGER RNA; OSU 03012; PROTEIN SUBUNIT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CATALYSIS; CELL LINEAGE; CELL SURVIVAL; ENZYME INHIBITION; MITOCHONDRIAL PERMEABILITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; B-LYMPHOCYTES; CATALYTIC DOMAIN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HUMANS; ISOXAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PYRAZOLES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; SULFONES;

EID: 37349131556     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0374-4     Document Type: Article

References (54)

1. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A (2005) COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26:1393-1399
2. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T (2004) Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 108:825-832
3. Dubois RN (2000) Review article: cyclooxygenase-a target for colon cancer prevention. Aliment Pharmacol Ther 14(Suppl 1):64-67
4. Samoha S, Arber N (2005) Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side. Oncology 69(Suppl 1):33-37
5. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, Ono M (2005) Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1beta-induced neovascularization and tumor growth. J Clin Invest 115:2979-2991
6. Zhi YH, Liu RS, Song MM, Tian Y, Long J, Tu W, Guo RX (2005) Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 11:3724-3728
7. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE (2004) Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 64:7439-7446
8. Park JH, Kang KH, Kim SH, Lee JH, Cho CM, Kweon YO, Kim SK, Choi YH, Bae HI, Kim MS (2005) Expression of Cyclooxygenase-2 and Bcl-2 in human gastric adenomas. Korean J Intern Med 20:198-204
9. Charames GS, Bapat B (2006) Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol 28:543-549
10. Han S, Roman J (2006) COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer 51(3):283-296
11. Palayoor ST, Arayankalayil MJ, Shoaibi A, Coleman CN (2005) Radiation sensitivity of human carcinoma cells transfected with small interfering RNA Targeted against cyclooxygenase-2. Clin Cancer Res 11:6980-6986
12. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E (2002) Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277:27613-27621
13. Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS (2002) The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366:831-837
14. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S (2005) Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Faseb J 19:1353-1355
15. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G (2004) Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47:550-557
16. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (2002) Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94:1745-1757
17. Phipps RP, Ryan E, Bernstein SH (2004) Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma? Leuk Res 28:109-111
18. Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I, Hakverdi S (2004) Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 45:1395-1399
19. Wun T, McKnight H, Tuscano JM (2004) Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 28:179-190
20. Secchiero P, Barbarotto E, Gonelli A, Tiribelli M, Zerbinati C, Celeghini C, Agostinelli C, Pileri SA, Zauli G (2005) Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells. Am J Pathol 167:1599-1607
21. Ryan EP, Pollock SJ, Kaur K, Felgar RE, Bernstein SH, Chiorrazi N, Phipps RP (2006) Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clin Immunol 120(1):76-90
22. Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, Peehl DM, Knox SJ (2002) Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 9:252-263
23. Ferraris AM, Rolfo M, Mangerini R, Gaetani GF (1994) Increased glutathione in chronic lymphocytic leukemia lymphocytes. Am J Hematol 47:237-238
24. Margalit A, Hauser SD, Zweifel BS, Anderson MA, Isakson PC (1998) Regulation of prostaglandin biosynthesis in vivo by glutathione. Am J Physiol 274:R294-R302
25. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF (2003) The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66:1499-1503
26. Fedyk ER, Phipps RP (1994) Reactive oxygen species and not lipoxygenase products are required for mouse B-lymphocyte activation and differentiation. Int J Immunopharmacol 16:533-546
27. Padilla J, Leung E, Phipps RP (2002) Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists. Clin Immunol 103:22-33
28. Ryan EP, Pollack SJ, Murant TI, Bernstein SH, Felgar RE, Phipps RP (2005) Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol 174:2619-2626
29. Kehry MR, Castle BE (1994) Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. Semin Immunol 6:287-294
30. Capone ML, Tacconelli S, Sciulli MG, Patrignani P (2003) Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 16:49-58
31. Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, Grever M, Chen CS, Byrd JC (2005) A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 105:2504-2509
32. Eady JJ, Orta T, Dennis MF, Stratford MR, Peacock JH (1995) Glutathione determination by the Tietze enzymatic recycling assay and its relationship to cellular radiation response. Br J Cancer 72:1089-1095
33. Staal FJ, Roederer M, Herzenberg LA, Herzenberg LA (1990) Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 87:9943-9947
34. Cerimele F, Battle T, Lynch R, Frank DA, Murad E, Cohen C, Macaron N, Sixbey J, Smith K, Watnick RS, Eliopoulos A, Shehata B, Arbiser JL (2005) Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci USA 102:175-179
35. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P (2003) Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101:4098-4104
36. George TC, Fanning SL, Fitzgeral-Bocarsly P, Medeiros RB, Highfill S, Shimizu Y, Hall BE, Frost K, Basiji D, Ortyn WE, Morrissey PJ, Lynch DH (2006) Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow. J Immunol Methods 311:117-129
37. Ortyn WE, Hall BE, George TC, Frost K, Basiji DA, Perry DJ, Zimmerman CA, Coder D, Morrissey PJ (2006) Sensitivity measurement and compensation in spectral imaging. Cytometry A 69:852-862
38. Ray DM, Akbiyik F, Phipps RP (2006) The peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) ligands 15-deoxy-{delta}12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPAR{gamma}-independent mechanisms. J Immunol 177:5068-5076
39. Inoue H, Takemura H, Kawai Y, Yoshida A, Ueda T, Miyashita T (2002) Dexamethasone-resistant human Pre-B leukemia 697 cell line evolving elevation of intracellular glutathione level: an additional resistance mechanism. Jpn J Cancer Res 93:582-590
40. Seelig GF, Simondsen RP, Meister A (1984) Reversible dissociation of gamma-glutamylcysteine synthetase into two subunits. J Biol Chem 259:9345-9347
41. Rahman I, Bel A, Mulier B, Lawson MF, Harrison DJ, Macnee W, Smith CA (1996) Transcriptional regulation of gamma-glutamylcysteine synthetase-heavy subunit by oxidants in human alveolar epithelial cells. Biochem Biophys Res Commun 229:832-837
42. Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10:175-176
43. Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM (2005) Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer 113:803-810
44. Jendrossek V, Handrick R, Belka C (2003) Celecoxib activates a novel mitochondrial apoptosis signaling pathway. Faseb J 17:1547-1549
45. Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, Grever M, Chen CS, Byrd JC (2005) A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma via a caspase and Bcl-2 independent mechanism. Blood 15; 105(6):2504-2509
46. Zhong H, Willard M, Simons J (2004) NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int J Cancer 112:585-595
47. Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P (2003) Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17:1437-1447
48. Nilsson J, Soderberg O, Nilsson K, Rosen A (2004) Differentiation- associated redox-regulation in human B cell lines from stem cell/pro-B to plasma cell. Immunol Lett 94:83-89
49. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716
50. Chu AJ, Chou TH, Chen BD (2004) Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front Biosci 9:2697-2713
51. Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE (2004) Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 96:305-315
52. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin's Lymphoma. Am J Epidemiol 157:510-516
53. Ellen T, Chang KEmS, Henrik Hjalgrim, Claudia Schöllkopf, Anna, Porwit-MacDonald CSm, Edneia Tani, Francesco d'Amore, Mads Melbye, Hans-Olov Adami aBG (2005) Medication use and risk of non-Hodgkin's Lymphoma. Am J Epidemiol 162:965-974
54. Rao CV, Reddy BS (2004) NSAIDs and chemoprevention. Curr Cancer Drug Targets 4:29-42